VoiceOps
By thread
voiceops@voiceops.org
By month
Messages by month
- ----- 2026 -----
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2025 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2024 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2023 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2022 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2021 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2020 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2019 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2018 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2017 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2016 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2015 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2014 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2013 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2012 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2011 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2010 -----
- December
- November
- October
- September
- August
- July
- June
- May
- April
- March
- February
- January
- ----- 2009 -----
- December
- November
- October
- September
- August
- July
- 14 participants
- 10512 messages
Malformed Caller ID
by ptimmins@clearrate.com
That sounds exactly like you're sending stuff that should be E.164 formatted out as 10 digit national. I looked up DeKalb IL and the first two digits of your area code are "81". Which is the country code for Japan. So your calls are being interpreted as +8157563626 instead of +18157563626 and a cell phone will show that as "Japan".
________________________________
From: VoiceOps <voiceops-bounces at voiceops.org> on behalf of Mike Hammett <voiceops at ics-il.net>
Sent: Thursday, April 22, 2021 6:38 PM
To: VoiceOps
Subject: Re: [VoiceOps] Malformed Caller ID
I finally got a number! It's suburban Chicago Sprint (now T-Mobile).
I guess that kind of throws the rural carrier idea out the window.
Apparently a non-zero number of people are expecting caller ID name to work on their mobile devices, but there are clearly caveats to that.
-----
Mike Hammett
Intelligent Computing Solutions
http://www.ics-il.com
Midwest Internet Exchange
http://www.midwest-ix.com
________________________________
From: "Mike Hammett" <voiceops at ics-il.net>
To: "VoiceOps" <voiceops at voiceops.org>
Sent: Thursday, April 22, 2021 4:01:02 PM
Subject: [VoiceOps] Malformed Caller ID
Have any of you noticed an increase in customer complaints of malformed caller ID?
We do a test call out as the customer, whether it's to one of our cell phones or one of the incumbent's POTS lines. Everything shows up as expected. The number is formatted correctly. The Caller ID name is formatted correctly.
However, we're getting customer complaints that the caller ID is saying Japan (we have nothing to do with Japan), United States, blank, or some other combination. We're just not able to confirm that.
Of course customers are reluctant to tell us what the numbers are of the remote parties having these issues, so we can't really look for common denominators.
-----
Mike Hammett
Intelligent Computing Solutions
http://www.ics-il.com
Midwest Internet Exchange
http://www.midwest-ix.com
_______________________________________________
VoiceOps mailing list
VoiceOps at voiceops.org
https://puck.nether.net/mailman/listinfo/voiceops
April 22, 2021
Malformed Caller ID
by voiceops@ics-il.net
I finally got a number! It's suburban Chicago Sprint (now T-Mobile).
I guess that kind of throws the rural carrier idea out the window.
Apparently a non-zero number of people are expecting caller ID name to work on their mobile devices, but there are clearly caveats to that.
-----
Mike Hammett
Intelligent Computing Solutions
http://www.ics-il.com
Midwest Internet Exchange
http://www.midwest-ix.com
----- Original Message -----
From: "Mike Hammett" <voiceops at ics-il.net>
To: "VoiceOps" <voiceops at voiceops.org>
Sent: Thursday, April 22, 2021 4:01:02 PM
Subject: [VoiceOps] Malformed Caller ID
Have any of you noticed an increase in customer complaints of malformed caller ID?
We do a test call out as the customer, whether it's to one of our cell phones or one of the incumbent's POTS lines. Everything shows up as expected. The number is formatted correctly. The Caller ID name is formatted correctly.
However, we're getting customer complaints that the caller ID is saying Japan (we have nothing to do with Japan), United States, blank, or some other combination. We're just not able to confirm that.
Of course customers are reluctant to tell us what the numbers are of the remote parties having these issues, so we can't really look for common denominators.
-----
Mike Hammett
Intelligent Computing Solutions
http://www.ics-il.com
Midwest Internet Exchange
http://www.midwest-ix.com
_______________________________________________
VoiceOps mailing list
VoiceOps at voiceops.org
https://puck.nether.net/mailman/listinfo/voiceops
April 22, 2021
Malformed Caller ID
by mjohnston@wiktel.com
The first thing I thought of was Least Cost Routing to a rural area. My
telco is rural. We see issues like that now and then. Setup the same
call over and over again and you will probably get a handful of
different CID/CNAM results at the recipient end.
Not saying this is your issue, but it is something we have experienced
over the past decade or so.
For those not familiar, here is a quick overview from the FFC:
https://www.fcc.gov/general/rural-call-completion-problems-long-distance-or…
April 22, 2021
Malformed Caller ID
by g.sandoval@chasedatacorp.com
Ran into this issue a long time ago, make sure you're passing callerID
strictly in E.164 format
On our end, it was only really an issue when calling into some rural
telecom companies and the virgin islands.
On Thu, Apr 22, 2021 at 5:05 PM Mike Hammett <voiceops at ics-il.net> wrote:
> Have any of you noticed an increase in customer complaints of malformed
> caller ID?
>
> We do a test call out as the customer, whether it's to one of our cell
> phones or one of the incumbent's POTS lines. Everything shows up as
> expected. The number is formatted correctly. The Caller ID name is
> formatted correctly.
>
>
> However, we're getting customer complaints that the caller ID is saying
> Japan (we have nothing to do with Japan), United States, blank, or some
> other combination. We're just not able to confirm that.
>
> Of course customers are reluctant to tell us what the numbers are of the
> remote parties having these issues, so we can't really look for common
> denominators.
>
>
>
> -----
> Mike Hammett
> Intelligent Computing Solutions
> http://www.ics-il.com
>
>
>
> Midwest Internet Exchange
> http://www.midwest-ix.com
>
>
>
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
>
April 22, 2021
Malformed Caller ID
by voiceops@ics-il.net
Have any of you noticed an increase in customer complaints of malformed caller ID?
We do a test call out as the customer, whether it's to one of our cell phones or one of the incumbent's POTS lines. Everything shows up as expected. The number is formatted correctly. The Caller ID name is formatted correctly.
However, we're getting customer complaints that the caller ID is saying Japan (we have nothing to do with Japan), United States, blank, or some other combination. We're just not able to confirm that.
Of course customers are reluctant to tell us what the numbers are of the remote parties having these issues, so we can't really look for common denominators.
-----
Mike Hammett
Intelligent Computing Solutions
http://www.ics-il.com
Midwest Internet Exchange
http://www.midwest-ix.com
April 22, 2021
Reputation Score Aggregator
by ciscoplumber@gmail.com
Does anyone know of a company that allows you to search the reputation of
an ANI across the various robocall mitigation companies and/or carriers?
For example instead of querying TNS, Neustar, Hiya, etc individually which
may not be possible without having their service, is there a company that
allows you to check the ANI against a variety of providers in one place?
Right now if a customer reports a mislabeled spam call we need to determine
the terminating carrier and work with them. This issue could also be
happening on multiple carriers (or robocall mitigation companies) and it
would be nice to see them all in one place.
Thanks
April 21, 2021
Phase III clinical trials of Kamailio DMQ
by jhellenthal@dataix.net
ROFL
Anyone paying attention to measured in kilograms ?
Happy April ! ?Fools?
--
J. Hellenthal
The fact that there's a highway to Hell but only a stairway to Heaven says a lot about anticipated traffic volume.
> On Apr 1, 2021, at 14:42, Carlos Alvarez <caalvarez at gmail.com> wrote:
>
> ?
> Right? Where do they find all these blind doctors?
>
>
>> On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <marylou at backuptelecom.com> wrote:
>> Maybe they should open their eyes instead of doing a double-blind study!
>> LOL!
>>
>> MARY LOU CAREY
>> BackUP Telecom Consulting
>> Office: 615-791-9969
>> Cell: 615-796-1111
>>
>> On 2021-04-01 02:27 PM, Hiers, David wrote:
>> > No AI here... This is classic, small-batch, hand-crafted, free-range,
>> > organic, gluten-free content.
>> >
>> >
>> > David
>> >
>> >
>> > -----Original Message-----
>> > From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex
>> > Balashov
>> > Sent: Thursday, April 1, 2021 12:18 PM
>> > To: Brandon Svec <bsvec at teamonesolutions.com>
>> > Cc: voiceops at voiceops.org
>> > Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
>> >
>> > Let me make sure I understand your question correctly: it is your
>> > belief or conjecture that this press release was automatically
>> > generated by a machine learning system?
>> >
>> > ?
>> > Sent from mobile, with due apologies for brevity and errors.
>> >
>> >> On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com>
>> >> wrote:
>> >>
>> >> ?GPT-3? Happy April Fools Day.
>> >>
>> >> Brandon
>> >>
>> >>> On Mar 31, 2021, at 9:47 PM, Alex Balashov
>> >>> <abalashov at evaristesys.com> wrote:
>> >>>
>> >>> ?For immediate release:
>> >>>
>> >>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
>> >>> with Posner | Palner Pharmaceuticals, are pleased to announce the
>> >>> eagerly anticipated start of Phase III clinical trials of Kamailio
>> >>> DMQ module replication.
>> >>>
>> >>> In this stage of the investigation of the promising replication
>> >>> scheme, which was developed in record time, DMQ will be tested in a
>> >>> rigourous, double-blind, controlled CI/CD process for large-scale
>> >>> efficacy and continually monitored for safety in shorter and longer
>> >>> terms.
>> >>>
>> >>> The now-concluded second phase established basic safety and Phase 2b
>> >>> entailed a dose-finding study for the optimal number of batched
>> >>> `dmq_usrloc` contacts per kilogram of cloud computing resource.
>> >>>
>> >>> The main cohort of the main sequence of the Phase III trial will
>> >>> enroll 380 randomly selected, statistically representative Floridian
>> >>> SIP registrars and
>> >>> 5700 SIP dialogs, also in the state of Florida. When asked about the
>> >>> disparity in the number of registrars versus dialogs, Alex Balashov
>> >>> of Evariste said, "It is reflective of the small number of SIP
>> >>> registrars in Florida; not to be indelicate, but consider the median
>> >>> age of the population."
>> >>>
>> >>> As previously remarked upon in proceedings of the World SIP
>> >>> Organisation (WSO), the choice of Florida as a venue attracted some
>> >>> questions. We asked Fred Posner of Posner | Palner about the clinical
>> >>> background informing this choice of replication study cohort:
>> >>>
>> >>> "Florida is a good place to find eventual consistency failures; the
>> >>> open climate and reluctance to accept traditional data integrity
>> >>> science would have sealed the deal, but when people started to drink
>> >>> bleach here, I saw an opportunity."
>> >>>
>> >>> Evariste and Posner | Palner are aiming for a US Food & Drug
>> >>> Administration EUA (Emergency Use Authorisation) for DMQ replication
>> >>> as a prophylactic data redundancy and failover measure to ward off
>> >>> the development of moderate to severe viral Sonus Haemorrhagic Fever
>> >>> symptoms.
>> >>>
>> >>> Phase II studies have painted a promising a picture of the DMQ
>> >>> architecture's ability to reduce moderate to severe symptoms and
>> >>> associated 28-day mortality by more than 90%, albeit over a small
>> >>> sample size and in enterprise patients with known pre-existing
>> >>> comorbidities such as Session Border Controller and BroadSoft
>> >>> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster
>> >>> quantums of broader efficacy, including efficacy for localised
>> >>> outbreaks of small to medium business softswitch.
>> >>>
>> >>> Of the control group, Balashov said, "They will receive a standard
>> >>> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
>> >>> confirmation messages. We proudly developed this approach in early
>> >>> 2020 in consultation with the highest levels of the Trump
>> >>> presidential administration; it is called TENP, or 'The Emperor's New
>> >>> Potion.' It is a successor to that administration's previous approved
>> >>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
>> >>>
>> >>> Despite speculative autism and packet fragmentation claims by Florida
>> >>> Governor Ron DeSantis, Balashov was quick to provide reassurance
>> >>> about side effects from DMQ in the Phase III trial.
>> >>>
>> >>> "The incidence of severe allergies to plain-text UDP was within
>> >>> standard deviation over the mean for all insecure replication, and
>> >>> there's support for other transports on the way. Anyway, we have a
>> >>> robust adverse effects reporting system in our issue tracker and
>> >>> solid surveillance. Don't let partisan politics dissuade you from
>> >>> allowing request lines with the KDMQ method."
>> >>>
>> >>> Other industry sources have reported that DMQ is not the only
>> >>> replication investigation undertaken by Evariste and Posner | Palner,
>> >>> although it is the only prophylactic suitable for the early infection
>> >>> development and inflammatory phases of a broad class of SBC-complex
>> >>> syndromes typically afflicting service providers. A recent IETF
>> >>> preprint by the same authors has shown high-quality preliminary data
>> >>> suggesting statistically significant improvement in morbidity
>> >>> outcomes from Perimeta and Nokia via a later-stage therapeutic
>> >>> intervention with a monoclonal, monorepo Github cocktail administered
>> >>> intravenously.
>> >>>
>> >>>
>> >>> --
>> >>> Alex Balashov | Principal | Evariste Systems LLC
>> >>>
>> >>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
>> >>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
>> >>> _______________________________________________
>> >>> VoiceOps mailing list
>> >>> VoiceOps at voiceops.org
>> >>> https://puck.nether.net/mailman/listinfo/voiceops
>> > _______________________________________________
>> > VoiceOps mailing list
>> > VoiceOps at voiceops.org
>> > https://puck.nether.net/mailman/listinfo/voiceops
>> >
>> > ----------------------------------------------------------------------
>> > This message and any attachments are intended only for the use of the
>> > addressee and may contain information that is privileged and
>> > confidential. If the reader of the message is not the intended
>> > recipient or an authorized representative of the intended recipient,
>> > you are hereby notified that any dissemination of this communication
>> > is strictly prohibited. If you have received this communication in
>> > error, notify the sender immediately by return email and delete the
>> > message and any attachments from your system.
>> > _______________________________________________
>> > VoiceOps mailing list
>> > VoiceOps at voiceops.org
>> > https://puck.nether.net/mailman/listinfo/voiceops
>> _______________________________________________
>> VoiceOps mailing list
>> VoiceOps at voiceops.org
>> https://puck.nether.net/mailman/listinfo/voiceops
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
April 2, 2021
Phase III clinical trials of Kamailio DMQ
by David.Hiers@cdk.com
Not GMO, but probably alcohol-infused.
From: Carlos Alvarez <caalvarez at gmail.com>
Sent: Thursday, April 1, 2021 12:36 PM
To: Hiers, David <David.Hiers at cdk.com>
Cc: Alex Balashov <abalashov at evaristesys.com>; Brandon Svec <bsvec at teamonesolutions.com>; voiceops at voiceops.org
Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
GMO?
On Thu, Apr 1, 2021 at 12:27 PM Hiers, David <David.Hiers at cdk.com<mailto:David.Hiers at cdk.com>> wrote:
No AI here... This is classic, small-batch, hand-crafted, free-range, organic, gluten-free content.
David
-----Original Message-----
From: VoiceOps <voiceops-bounces at voiceops.org<mailto:voiceops-bounces at voiceops.org>> On Behalf Of Alex Balashov
Sent: Thursday, April 1, 2021 12:18 PM
To: Brandon Svec <bsvec at teamonesolutions.com<mailto:bsvec at teamonesolutions.com>>
Cc: voiceops at voiceops.org<mailto:voiceops at voiceops.org>
Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
Let me make sure I understand your question correctly: it is your belief or conjecture that this press release was automatically generated by a machine learning system?
?
Sent from mobile, with due apologies for brevity and errors.
> On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com<mailto:bsvec at teamonesolutions.com>> wrote:
>
> ?GPT-3? Happy April Fools Day.
>
> Brandon
>
>> On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com<mailto:abalashov at evaristesys.com>> wrote:
>>
>> ?For immediate release:
>>
>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
>> with Posner | Palner Pharmaceuticals, are pleased to announce the
>> eagerly anticipated start of Phase III clinical trials of Kamailio
>> DMQ module replication.
>>
>> In this stage of the investigation of the promising replication
>> scheme, which was developed in record time, DMQ will be tested in a
>> rigourous, double-blind, controlled CI/CD process for large-scale
>> efficacy and continually monitored for safety in shorter and longer terms.
>>
>> The now-concluded second phase established basic safety and Phase 2b
>> entailed a dose-finding study for the optimal number of batched
>> `dmq_usrloc` contacts per kilogram of cloud computing resource.
>>
>> The main cohort of the main sequence of the Phase III trial will
>> enroll 380 randomly selected, statistically representative Floridian
>> SIP registrars and
>> 5700 SIP dialogs, also in the state of Florida. When asked about the
>> disparity in the number of registrars versus dialogs, Alex Balashov
>> of Evariste said, "It is reflective of the small number of SIP
>> registrars in Florida; not to be indelicate, but consider the median age of the population."
>>
>> As previously remarked upon in proceedings of the World SIP
>> Organisation (WSO), the choice of Florida as a venue attracted some
>> questions. We asked Fred Posner of Posner | Palner about the clinical
>> background informing this choice of replication study cohort:
>>
>> "Florida is a good place to find eventual consistency failures; the
>> open climate and reluctance to accept traditional data integrity
>> science would have sealed the deal, but when people started to drink
>> bleach here, I saw an opportunity."
>>
>> Evariste and Posner | Palner are aiming for a US Food & Drug
>> Administration EUA (Emergency Use Authorisation) for DMQ replication
>> as a prophylactic data redundancy and failover measure to ward off
>> the development of moderate to severe viral Sonus Haemorrhagic Fever symptoms.
>>
>> Phase II studies have painted a promising a picture of the DMQ
>> architecture's ability to reduce moderate to severe symptoms and
>> associated 28-day mortality by more than 90%, albeit over a small
>> sample size and in enterprise patients with known pre-existing
>> comorbidities such as Session Border Controller and BroadSoft
>> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster
>> quantums of broader efficacy, including efficacy for localised outbreaks of small to medium business softswitch.
>>
>> Of the control group, Balashov said, "They will receive a standard
>> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
>> confirmation messages. We proudly developed this approach in early
>> 2020 in consultation with the highest levels of the Trump
>> presidential administration; it is called TENP, or 'The Emperor's New
>> Potion.' It is a successor to that administration's previous approved placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
>>
>> Despite speculative autism and packet fragmentation claims by Florida
>> Governor Ron DeSantis, Balashov was quick to provide reassurance
>> about side effects from DMQ in the Phase III trial.
>>
>> "The incidence of severe allergies to plain-text UDP was within
>> standard deviation over the mean for all insecure replication, and
>> there's support for other transports on the way. Anyway, we have a
>> robust adverse effects reporting system in our issue tracker and
>> solid surveillance. Don't let partisan politics dissuade you from allowing request lines with the KDMQ method."
>>
>> Other industry sources have reported that DMQ is not the only
>> replication investigation undertaken by Evariste and Posner | Palner,
>> although it is the only prophylactic suitable for the early infection
>> development and inflammatory phases of a broad class of SBC-complex
>> syndromes typically afflicting service providers. A recent IETF
>> preprint by the same authors has shown high-quality preliminary data
>> suggesting statistically significant improvement in morbidity
>> outcomes from Perimeta and Nokia via a later-stage therapeutic intervention with a monoclonal, monorepo Github cocktail administered intravenously.
>>
>>
>> --
>> Alex Balashov | Principal | Evariste Systems LLC
>>
>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
>> Web: http://www.evaristesys.com/<https://urldefense.proofpoint.com/v2/url?u=http-3A__www.evaristesys.com_&d=…>, http://www.csrpswitch.com/<https://urldefense.proofpoint.com/v2/url?u=http-3A__www.csrpswitch.com_&d=D…>
>> _______________________________________________
>> VoiceOps mailing list
>> VoiceOps at voiceops.org<mailto:VoiceOps at voiceops.org>
>> https://puck.nether.net/mailman/listinfo/voiceops<https://urldefense.proofpoint.com/v2/url?u=https-3A__puck.nether.net_mailma…>
_______________________________________________
VoiceOps mailing list
VoiceOps at voiceops.org<mailto:VoiceOps at voiceops.org>
https://puck.nether.net/mailman/listinfo/voiceops<https://urldefense.proofpoint.com/v2/url?u=https-3A__puck.nether.net_mailma…>
----------------------------------------------------------------------
This message and any attachments are intended only for the use of the addressee and may contain information that is privileged and confidential. If the reader of the message is not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any dissemination of this communication is strictly prohibited. If you have received this communication in error, notify the sender immediately by return email and delete the message and any attachments from your system.
_______________________________________________
VoiceOps mailing list
VoiceOps at voiceops.org<mailto:VoiceOps at voiceops.org>
https://puck.nether.net/mailman/listinfo/voiceops<https://urldefense.proofpoint.com/v2/url?u=https-3A__puck.nether.net_mailma…>
April 1, 2021
Phase III clinical trials of Kamailio DMQ
by caalvarez@gmail.com
Right? Where do they find all these blind doctors?
On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <marylou at backuptelecom.com>
wrote:
> Maybe they should open their eyes instead of doing a double-blind study!
> LOL!
>
> MARY LOU CAREY
> BackUP Telecom Consulting
> Office: 615-791-9969
> Cell: 615-796-1111
>
> On 2021-04-01 02:27 PM, Hiers, David wrote:
> > No AI here... This is classic, small-batch, hand-crafted, free-range,
> > organic, gluten-free content.
> >
> >
> > David
> >
> >
> > -----Original Message-----
> > From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex
> > Balashov
> > Sent: Thursday, April 1, 2021 12:18 PM
> > To: Brandon Svec <bsvec at teamonesolutions.com>
> > Cc: voiceops at voiceops.org
> > Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
> >
> > Let me make sure I understand your question correctly: it is your
> > belief or conjecture that this press release was automatically
> > generated by a machine learning system?
> >
> > ?
> > Sent from mobile, with due apologies for brevity and errors.
> >
> >> On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com>
> >> wrote:
> >>
> >> ?GPT-3? Happy April Fools Day.
> >>
> >> Brandon
> >>
> >>> On Mar 31, 2021, at 9:47 PM, Alex Balashov
> >>> <abalashov at evaristesys.com> wrote:
> >>>
> >>> ?For immediate release:
> >>>
> >>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
> >>> with Posner | Palner Pharmaceuticals, are pleased to announce the
> >>> eagerly anticipated start of Phase III clinical trials of Kamailio
> >>> DMQ module replication.
> >>>
> >>> In this stage of the investigation of the promising replication
> >>> scheme, which was developed in record time, DMQ will be tested in a
> >>> rigourous, double-blind, controlled CI/CD process for large-scale
> >>> efficacy and continually monitored for safety in shorter and longer
> >>> terms.
> >>>
> >>> The now-concluded second phase established basic safety and Phase 2b
> >>> entailed a dose-finding study for the optimal number of batched
> >>> `dmq_usrloc` contacts per kilogram of cloud computing resource.
> >>>
> >>> The main cohort of the main sequence of the Phase III trial will
> >>> enroll 380 randomly selected, statistically representative Floridian
> >>> SIP registrars and
> >>> 5700 SIP dialogs, also in the state of Florida. When asked about the
> >>> disparity in the number of registrars versus dialogs, Alex Balashov
> >>> of Evariste said, "It is reflective of the small number of SIP
> >>> registrars in Florida; not to be indelicate, but consider the median
> >>> age of the population."
> >>>
> >>> As previously remarked upon in proceedings of the World SIP
> >>> Organisation (WSO), the choice of Florida as a venue attracted some
> >>> questions. We asked Fred Posner of Posner | Palner about the clinical
> >>> background informing this choice of replication study cohort:
> >>>
> >>> "Florida is a good place to find eventual consistency failures; the
> >>> open climate and reluctance to accept traditional data integrity
> >>> science would have sealed the deal, but when people started to drink
> >>> bleach here, I saw an opportunity."
> >>>
> >>> Evariste and Posner | Palner are aiming for a US Food & Drug
> >>> Administration EUA (Emergency Use Authorisation) for DMQ replication
> >>> as a prophylactic data redundancy and failover measure to ward off
> >>> the development of moderate to severe viral Sonus Haemorrhagic Fever
> >>> symptoms.
> >>>
> >>> Phase II studies have painted a promising a picture of the DMQ
> >>> architecture's ability to reduce moderate to severe symptoms and
> >>> associated 28-day mortality by more than 90%, albeit over a small
> >>> sample size and in enterprise patients with known pre-existing
> >>> comorbidities such as Session Border Controller and BroadSoft
> >>> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster
> >>> quantums of broader efficacy, including efficacy for localised
> >>> outbreaks of small to medium business softswitch.
> >>>
> >>> Of the control group, Balashov said, "They will receive a standard
> >>> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
> >>> confirmation messages. We proudly developed this approach in early
> >>> 2020 in consultation with the highest levels of the Trump
> >>> presidential administration; it is called TENP, or 'The Emperor's New
> >>> Potion.' It is a successor to that administration's previous approved
> >>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
> >>>
> >>> Despite speculative autism and packet fragmentation claims by Florida
> >>> Governor Ron DeSantis, Balashov was quick to provide reassurance
> >>> about side effects from DMQ in the Phase III trial.
> >>>
> >>> "The incidence of severe allergies to plain-text UDP was within
> >>> standard deviation over the mean for all insecure replication, and
> >>> there's support for other transports on the way. Anyway, we have a
> >>> robust adverse effects reporting system in our issue tracker and
> >>> solid surveillance. Don't let partisan politics dissuade you from
> >>> allowing request lines with the KDMQ method."
> >>>
> >>> Other industry sources have reported that DMQ is not the only
> >>> replication investigation undertaken by Evariste and Posner | Palner,
> >>> although it is the only prophylactic suitable for the early infection
> >>> development and inflammatory phases of a broad class of SBC-complex
> >>> syndromes typically afflicting service providers. A recent IETF
> >>> preprint by the same authors has shown high-quality preliminary data
> >>> suggesting statistically significant improvement in morbidity
> >>> outcomes from Perimeta and Nokia via a later-stage therapeutic
> >>> intervention with a monoclonal, monorepo Github cocktail administered
> >>> intravenously.
> >>>
> >>>
> >>> --
> >>> Alex Balashov | Principal | Evariste Systems LLC
> >>>
> >>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
> >>> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
> >>> _______________________________________________
> >>> VoiceOps mailing list
> >>> VoiceOps at voiceops.org
> >>> https://puck.nether.net/mailman/listinfo/voiceops
> > _______________________________________________
> > VoiceOps mailing list
> > VoiceOps at voiceops.org
> > https://puck.nether.net/mailman/listinfo/voiceops
> >
> > ----------------------------------------------------------------------
> > This message and any attachments are intended only for the use of the
> > addressee and may contain information that is privileged and
> > confidential. If the reader of the message is not the intended
> > recipient or an authorized representative of the intended recipient,
> > you are hereby notified that any dissemination of this communication
> > is strictly prohibited. If you have received this communication in
> > error, notify the sender immediately by return email and delete the
> > message and any attachments from your system.
> > _______________________________________________
> > VoiceOps mailing list
> > VoiceOps at voiceops.org
> > https://puck.nether.net/mailman/listinfo/voiceops
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
>
April 1, 2021
Phase III clinical trials of Kamailio DMQ
by caalvarez@gmail.com
GMO?
On Thu, Apr 1, 2021 at 12:27 PM Hiers, David <David.Hiers at cdk.com> wrote:
> No AI here... This is classic, small-batch, hand-crafted, free-range,
> organic, gluten-free content.
>
>
> David
>
>
> -----Original Message-----
> From: VoiceOps <voiceops-bounces at voiceops.org> On Behalf Of Alex Balashov
> Sent: Thursday, April 1, 2021 12:18 PM
> To: Brandon Svec <bsvec at teamonesolutions.com>
> Cc: voiceops at voiceops.org
> Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ
>
> Let me make sure I understand your question correctly: it is your belief
> or conjecture that this press release was automatically generated by a
> machine learning system?
>
> ?
> Sent from mobile, with due apologies for brevity and errors.
>
> > On Apr 1, 2021, at 3:10 PM, Brandon Svec <bsvec at teamonesolutions.com>
> wrote:
> >
> > ?GPT-3? Happy April Fools Day.
> >
> > Brandon
> >
> >> On Mar 31, 2021, at 9:47 PM, Alex Balashov <abalashov at evaristesys.com>
> wrote:
> >>
> >> ?For immediate release:
> >>
> >> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership
> >> with Posner | Palner Pharmaceuticals, are pleased to announce the
> >> eagerly anticipated start of Phase III clinical trials of Kamailio
> >> DMQ module replication.
> >>
> >> In this stage of the investigation of the promising replication
> >> scheme, which was developed in record time, DMQ will be tested in a
> >> rigourous, double-blind, controlled CI/CD process for large-scale
> >> efficacy and continually monitored for safety in shorter and longer
> terms.
> >>
> >> The now-concluded second phase established basic safety and Phase 2b
> >> entailed a dose-finding study for the optimal number of batched
> >> `dmq_usrloc` contacts per kilogram of cloud computing resource.
> >>
> >> The main cohort of the main sequence of the Phase III trial will
> >> enroll 380 randomly selected, statistically representative Floridian
> >> SIP registrars and
> >> 5700 SIP dialogs, also in the state of Florida. When asked about the
> >> disparity in the number of registrars versus dialogs, Alex Balashov
> >> of Evariste said, "It is reflective of the small number of SIP
> >> registrars in Florida; not to be indelicate, but consider the median
> age of the population."
> >>
> >> As previously remarked upon in proceedings of the World SIP
> >> Organisation (WSO), the choice of Florida as a venue attracted some
> >> questions. We asked Fred Posner of Posner | Palner about the clinical
> >> background informing this choice of replication study cohort:
> >>
> >> "Florida is a good place to find eventual consistency failures; the
> >> open climate and reluctance to accept traditional data integrity
> >> science would have sealed the deal, but when people started to drink
> >> bleach here, I saw an opportunity."
> >>
> >> Evariste and Posner | Palner are aiming for a US Food & Drug
> >> Administration EUA (Emergency Use Authorisation) for DMQ replication
> >> as a prophylactic data redundancy and failover measure to ward off
> >> the development of moderate to severe viral Sonus Haemorrhagic Fever
> symptoms.
> >>
> >> Phase II studies have painted a promising a picture of the DMQ
> >> architecture's ability to reduce moderate to severe symptoms and
> >> associated 28-day mortality by more than 90%, albeit over a small
> >> sample size and in enterprise patients with known pre-existing
> >> comorbidities such as Session Border Controller and BroadSoft
> >> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster
> >> quantums of broader efficacy, including efficacy for localised
> outbreaks of small to medium business softswitch.
> >>
> >> Of the control group, Balashov said, "They will receive a standard
> >> pipe-to-/dev/null placebo protocol, but with identical '200 OK'
> >> confirmation messages. We proudly developed this approach in early
> >> 2020 in consultation with the highest levels of the Trump
> >> presidential administration; it is called TENP, or 'The Emperor's New
> >> Potion.' It is a successor to that administration's previous approved
> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."
> >>
> >> Despite speculative autism and packet fragmentation claims by Florida
> >> Governor Ron DeSantis, Balashov was quick to provide reassurance
> >> about side effects from DMQ in the Phase III trial.
> >>
> >> "The incidence of severe allergies to plain-text UDP was within
> >> standard deviation over the mean for all insecure replication, and
> >> there's support for other transports on the way. Anyway, we have a
> >> robust adverse effects reporting system in our issue tracker and
> >> solid surveillance. Don't let partisan politics dissuade you from
> allowing request lines with the KDMQ method."
> >>
> >> Other industry sources have reported that DMQ is not the only
> >> replication investigation undertaken by Evariste and Posner | Palner,
> >> although it is the only prophylactic suitable for the early infection
> >> development and inflammatory phases of a broad class of SBC-complex
> >> syndromes typically afflicting service providers. A recent IETF
> >> preprint by the same authors has shown high-quality preliminary data
> >> suggesting statistically significant improvement in morbidity
> >> outcomes from Perimeta and Nokia via a later-stage therapeutic
> intervention with a monoclonal, monorepo Github cocktail administered
> intravenously.
> >>
> >>
> >> --
> >> Alex Balashov | Principal | Evariste Systems LLC
> >>
> >> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)
> >> Web: http://www.evaristesys.com/, http://www.csrpswitch.com/
> >> _______________________________________________
> >> VoiceOps mailing list
> >> VoiceOps at voiceops.org
> >> https://puck.nether.net/mailman/listinfo/voiceops
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
>
> ----------------------------------------------------------------------
> This message and any attachments are intended only for the use of the
> addressee and may contain information that is privileged and confidential.
> If the reader of the message is not the intended recipient or an authorized
> representative of the intended recipient, you are hereby notified that any
> dissemination of this communication is strictly prohibited. If you have
> received this communication in error, notify the sender immediately by
> return email and delete the message and any attachments from your system.
> _______________________________________________
> VoiceOps mailing list
> VoiceOps at voiceops.org
> https://puck.nether.net/mailman/listinfo/voiceops
>
April 1, 2021